New research indicates that people who discontinue popular slimming jabs like semaglutide or tirzepatide may regain reduced body mass far faster than those who halt traditional lifestyle programs.
Published data in a prominent health publication demonstrates that while overweight individuals often shed a large proportion of their body weight while on the medication, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"People using such treatments should be aware of the risk of fast rebound weight gain when the treatment is stopped," stated researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment mass within about 18 months.
Weighing Treatments
The analysis, which reviewed dozens of studies involving thousands of patients, contrasted the results of GLP-1 agonists with conventional dieting.
Scientists point out that people who shed pounds through dieting generally have a slower creep back—around 0.1 kg a month—after stopping.
Explaining the Fast Rebound
Experts believe the mode of action of the jabs explains the accelerated weight return.
These medications imitate a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than normal might result in the system to generate a reduced amount of its endogenous hormone, and could reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making overeating much more probable."
A Chronic Condition?
The NHS recommend the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, due to the high risk of weight regain, the treatment is often long-term.
This view is supported by pharmaceutical companies, who note that the findings "highlight the persistent character of obesity," comparing it to managing diseases like diabetes.
Patient Accounts
People who have stopped the jabs report a sudden resurgence of cravings.
"I experienced something activating and you're instantly extremely hungry," described a patient.
This difficulty is exacerbated if patients have not adopted permanent lifestyle or habit changes during treatment.
Widespread Adoption
Survey data indicate that millions of people in the UK have used weight-loss jabs in the past year, with demand remaining high.
- Adoption is more common among women than men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and lasting health benefits relies on combined behavioural management.
